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However, the blurb of the book is a little misleading because the evaluation of HER2, EGFR family members, p53 and UPA/PAI-1 are not only the highlights but the sole biomarkers evaluated in detail. As estrogen receptor (ER), progesterone receptor (PgR), Her-2/neu, epidermal growth factor receptor (EGF-R), p53 and bcl-2 (not discussed in the book) are well-known markers, unfortunately the book offers nothing new in this respect to readers working in the field. According to the long production process this book seemingly needed, the listed references for each chapter are almost two years old. Especially in fields with fast-evolving knowledge due to the application of new techniques which are also presented in the book and discussed in the future directions section, the content of the book is behind the common knowledge at the day of printing. However, this is a problem every book has to face. The book is addressed to laboratory investigators developing new tumor markers, clinical investigators testing them, and clinicians using them. As the chapters are written in a review style the book provides a state-ofthe-art overview at least until 2004 for readers seeking a general idea of the progress in the field of biomarkers in breast cancer and for those entering the field. Norbert Arnold, Kiel
